Connor, Clark & Lunn Investment Management Ltd. Entrada Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 11,553 shares of TRDA stock, worth $83,297. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,553
Previous 85,621
86.51%
Holding current value
$83,297
Previous $1.48 Million
92.97%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding TRDA
# of Institutions
111Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$35.1 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$31.8 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$31.6 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$19.7 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$15.3 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $226M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...